TxCell gains CAR-Tregs patent for autoimmune and inflammatory diseases

22 June 2016

French biotech TxCell (Euronext Paris: TXCL) has received a patent covering all redirected, genetically engineered T regulatory cells (CAR Tregs) and their use in the suppression of autoimmune and inflammatory diseases from the European Patent Office.

As a result, TxCell has exercised its option and signed an exclusive worldwide licensing agreement with Yeda Research and Development, the technology transfer arm of the Weizmann Institute of Science in Rehovot, Israel, and owner of the patent.

This means TxCell has now been granted exclusive worldwide rights to develop and commercialize CAR-Treg products for the treatment of autoimmune and inflammatory diseases, as covered by the patent family.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK